Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

Table 1 Demographic, clinical and laboratory characteristics of patients in the study group

Variable		AML^{DNMT3A/FLT3/NPM1}	Other*	P-value
Age (years)	Median	56.00	62.00	0.025
	Range	29-81	21-91
Sex	Female (%)	23 (65.7)	67 (46.9)	0.045
	Male (%)	12 (34.3)	76 (53.1)
BM Blast % (range)	Median	83.5 (29-98)	71.0 (20-99)	<0.001
Hemoglobin g/dL (range)	Median	9.6 (6-13)	9.3 (6-14.3)	0.683
WBC 10³/μL (range)	Median	50.9 (0.1-298)	19.0 (0.3-297)	0.006
Monocytes 10³/μL (range)	Median	4.0 (0-76)	5.0 (0-73)	0.960
Platelets 10³/μL (range)	Median	45.0 (7-218)	50.0 (8-1069)	0.397
PB Blast % (range)	Median	46.0 (0-99)	23.0 (0-99)	0.191
CG Risk Group %^†	Intermediate	91.4	80.4	0.168
	Poor	2.9	14.0
CN-AML%		87.5	67.4	0.024

*Includes: All mutation groups other than AML^{DNMT3A/FLT3/NPM1}.
Abbreviations: AML acute myeloid leukemia, BM bone marrow, PB peripheral blood, WBC white blood cell count, CG cytogenetic, CN-AML cytogenetically normal AML.
Bold font indicates parameters with significant differences between groups.

ISSN: 1756-8722